Sugi Predict

Sugi Predict / Targets / RPA1

RPA1

Replication protein A 70 kDa DNA-binding subunit · P27694 · RPA1 on Sugi Atlas →

8,661 patent compounds predicted against RPA1, 5,095 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1986774 SCHEMBL1986774 0.77 16/20
SCHEMBL1514551 SCHEMBL1514551 0.76 14/20
SCHEMBL1765042 SCHEMBL1765042 0.64 14/20
SCHEMBL629223 SCHEMBL629223 0.58 14/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL629222) 0.57 14/20
SCHEMBL1765059 SCHEMBL1765059 0.57 12/20
SCHEMBL2565079 SCHEMBL2565079 0.56 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2560751) 0.55 12/20
SCHEMBL1514562 SCHEMBL1514562 0.85 11/20
SCHEMBL1765068 SCHEMBL1765068 0.70 11/20
SCHEMBL1765454 SCHEMBL1765454 0.65 11/20
SCHEMBL1764965 SCHEMBL1764965 0.65 11/20
SCHEMBL1765497 SCHEMBL1765497 0.64 11/20
SCHEMBL1765255 SCHEMBL1765255 0.61 11/20
SCHEMBL1526212 SCHEMBL1526212 0.61 11/20
SCHEMBL1765503 SCHEMBL1765503 0.61 11/20
SCHEMBL1765411 SCHEMBL1765411 0.56 11/20
SCHEMBL2319936 SCHEMBL2319936 0.54 11/20
SCHEMBL1764873 SCHEMBL1764873 0.64 10/20
SCHEMBL1764940 SCHEMBL1764940 0.60 10/20

Clinical trials — most relevant to RPA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers PHASE1/PHASE2COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation PHASE2COMPLETED
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers PHASE1RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE
Prognostic Biomarkers in Patients With Urothelial Carcinoma nanCOMPLETED
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
Vascular Senescence and Atherosclerotic Plaque Vulnerability nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RPA1 binder may also engage these)

ProteinNameSimilarity
Q5R7Q4 — 1.000 Q5R7Q4 →
Q8VEE4 — 1.000 Q8VEE4 →
Q01588 — 0.998 Q01588 →
Q6NY74 — 0.996 Q6NY74 →
Q5ZJJ2 — 0.994 Q5ZJJ2 →
Q5FW17 — 0.991 Q5FW17 →
Q24492 — 0.968 Q24492 →
Q92372 — 0.965 Q92372 →
Q60446 — 0.949 Q60446 →
HSPH1 Heat shock protein 105 kDa 0.948 landscape →
Q3SZ19 — 0.946 Q3SZ19 →
P48722 — 0.946 P48722 →
Q5R606 — 0.946 Q5R606 →
F4HQD4 — 0.945 F4HQD4 →
Q9SKI4 — 0.945 Q9SKI4 →
Q5RGJ5 — 0.945 Q5RGJ5 →
Q9SDK9 — 0.944 Q9SDK9 →
Q61699 — 0.944 Q61699 →
Q9S7C0 — 0.944 Q9S7C0 →
Q28F51 — 0.943 Q28F51 →
Q9LXK1 — 0.943 Q9LXK1 →
Q66HA8 — 0.943 Q66HA8 →
Q5RC43 — 0.943 Q5RC43 →
Q5RAE1 — 0.943 Q5RAE1 →
A0A7U2QYM2 — 0.942 A0A7U2QYM2 →
Q6NLG7 — 0.942 Q6NLG7 →
Q9H1D9 — 0.942 Q9H1D9 →
PSMD9 26S proteasome non-ATPase regulatory subunit 9 0.942 landscape →
Q93Y22 — 0.942 Q93Y22 →
O62621 — 0.942 O62621 →